Literature DB >> 24561794

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

Franz J Gassner1, Nadja Zaborsky, Daniel Neureiter, Michael Huemer, Thomas Melchardt, Alexander Egle, Stefan Rebhandl, Kemal Catakovic, Tanja N Hartmann, Richard Greil, Roland Geisberger.   

Abstract

Entities:  

Keywords:  T cell imhibitory receptors; chronic lymphocytic leukemia; lenalidomide

Mesh：

Substances：

Year:  2014        PMID： 24561794      PMCID： PMC4008106          DOI： 10.3324/haematol.2013.098459

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

Review 2.  CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.

Authors:  Marius Strioga; Vita Pasukoniene; Dainius Characiejus
Journal:  Immunology       Date:  2011-06-29       Impact factor: 7.397

3.  Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

Authors:  Tait D Shanafelt; Alan G Ramsay; Clive S Zent; Jose F Leis; Han W Tun; Timothy G Call; Betsy LaPlant; Deborah Bowen; Adam Pettinger; Diane F Jelinek; Curtis A Hanson; Neil E Kay
Journal:  Blood       Date:  2013-03-14       Impact factor: 22.113

Review 4.  Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells.

Authors:  Ben Youngblood; E John Wherry; Rafi Ahmed
Journal:  Curr Opin HIV AIDS       Date:  2012-01       Impact factor: 4.283

5.  Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction.

Authors:  Brent E Palmer; Naomi Blyveis; Andrew P Fontenot; Cara C Wilson
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

6.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Authors:  Alan G Ramsay; Andrew J Clear; Rewas Fatah; John G Gribben
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

7.  CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.

Authors:  Richard V Parry; Jens M Chemnitz; Kenneth A Frauwirth; Anthony R Lanfranco; Inbal Braunstein; Sumire V Kobayashi; Peter S Linsley; Craig B Thompson; James L Riley
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

8.  Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals.

Authors:  S Chidrawar; N Khan; W Wei; A McLarnon; N Smith; L Nayak; P Moss
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

Review 9.  The immunodeficiency of chronic lymphocytic leukaemia.

Authors:  A D Hamblin; T J Hamblin
Journal:  Br Med Bull       Date:  2008-08-27       Impact factor: 4.291

10.  Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

Authors:  Franz Josef Gassner; Lukas Weiss; Roland Geisberger; Josefina Piñón Hofbauer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil; Inge Tinhofer
Journal:  Cancer Immunol Immunother       Date:  2010-09-21       Impact factor: 6.968
View more
  18 in total

Review 1.  Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.

Authors:  Diana C G Bouhassira; Joshua J Thompson; Marco L Davila
Journal:  Expert Opin Biol Ther       Date:  2015-02-09       Impact factor: 4.388

2.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

Authors:  Elly Marcq; Vasiliki Siozopoulou; Jorrit De Waele; Jonas van Audenaerde; Karen Zwaenepoel; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

3.  B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.

Authors:  Nadja Zaborsky; Claudia Holler; Roland Geisberger; Daniela Asslaber; Franz Josef Gassner; Viktoria Egger; Josephina Piñón-Hofbauer; Thomas Kocher; Tanja Nicole Hartmann; Richard Greil; Alexander Egle
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

4.  Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.

Authors:  Franz J Gassner; Nadja Zaborsky; Kemal Catakovic; Stefan Rebhandl; Michael Huemer; Alexander Egle; Tanja N Hartmann; Richard Greil; Roland Geisberger
Journal:  Br J Haematol       Date:  2015-05-04       Impact factor: 6.998

5.  T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.

Authors:  Ceri E Oldreive; Anna Skowronska; Nicholas J Davies; Helen Parry; Angelo Agathanggelou; Sergey Krysov; Graham Packham; Zbigniew Rudzki; Laura Cronin; Katerina Vrzalikova; Paul Murray; Elena Odintsova; Guy Pratt; A Malcolm R Taylor; Paul Moss; Tatjana Stankovic
Journal:  Dis Model Mech       Date:  2015-08-20       Impact factor: 5.758

6.  CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.

Authors:  Nadja Zaborsky; Franz Josef Gassner; Daniela Asslaber; Petra Reinthaler; Ursula Denk; Sabine Flenady; Josefina Piñón Hofbauer; Barbara Danner; Stefan Rebhandl; Andrea Harrer; Roland Geisberger; Richard Greil; Alexander Egle
Journal:  Oncotarget       Date:  2016-08-02

7.  Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Authors:  Maria Winqvist; Fariba Mozaffari; Marzia Palma; Sandra Eketorp Sylvan; Lotta Hansson; Håkan Mellstedt; Anders Österborg; Jeanette Lundin
Journal:  Cancer Immunol Immunother       Date:  2016-11-04       Impact factor: 6.968

Review 8.  T cell exhaustion: from pathophysiological basics to tumor immunotherapy.

Authors:  Kemal Catakovic; Eckhard Klieser; Daniel Neureiter; Roland Geisberger
Journal:  Cell Commun Signal       Date:  2017-01-05       Impact factor: 5.712

9.  TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.

Authors:  Kemal Catakovic; Franz Josef Gassner; Christoph Ratswohl; Nadja Zaborsky; Stefan Rebhandl; Maria Schubert; Markus Steiner; Julia Christine Gutjahr; Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil; Roland Geisberger
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

10.  T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.

Authors:  Frauke M Schnorfeil; Felix S Lichtenegger; Katharina Emmerig; Miriam Schlueter; Julia S Neitz; Rika Draenert; Wolfgang Hiddemann; Marion Subklewe
Journal:  J Hematol Oncol       Date:  2015-07-30       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.